comparemela.com
Home
Live Updates
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER : comparemela.com
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased...
Related Keywords
Australia ,
United States ,
Sydney ,
New South Wales ,
American ,
Jeffrey Rubens ,
Genentech ,
Drug Administration ,
American Association Of Cancer Research ,
Oncology Consortium ,
St Jude Children Research Hospital In Memphis ,
Kazia Therapeutics Limited ,
Drug Administration Safety ,
Kazia Therapeutics ,
United States Food ,
Rare Pediatric Disease Designation ,
Pediatric Disease Designation ,
Professor Jeffrey Rubens ,
American Association ,
Cancer Research ,
Annual Meeting ,
New Orleans ,
Innovation Act ,
Rare Pediatric Disease Priority Review Voucher ,
Pacific Pediatric Neuro Oncology Consortium ,
Research Hospital ,
Therapeutics Limited ,
Orphan Drug Designation ,
Fast Track Designation ,
Orphan Designation ,
comparemela.com © 2020. All Rights Reserved.